AIM AIM ImmunoTech Inc.

2.51
-0.04  -2%
Previous Close 2.55
Open 2.49
Price To Book 4.25
Market Cap 69,341,453
Shares 27,626,077
Volume 1,621,502
Short Ratio 0.12
Av. Daily Volume 10,506,538
Stock charts supplied by TradingView

NewsSee all news

  1. AIM ImmunoTech and Shenzhen Smoore Technology Announce an Agreement to Research Utilizing an Innovative Smoore Inhalation Delivery Device and Ampligen (rintatolimod) as a Potential, Easy-To-Use Treatment Approach for the SARS-CoV-2 Pandemic

  2. AIM ImmunoTech Inc. General Corporate Statement (Form8) (0001493152-20-005912)

  3. AIM ImmunoTech and Shenzhen Smoore Technology Announce an Agreement to Research Utilizing an Innovative Smoore Inhalation Delivery Device and Ampligen (rintatolimod) as a Potential, Easy-To-Use Treatment Approach for the SARS-CoV-2 Pandemic

    OCALA, FL / ACCESSWIRE / April 6, 2020 / AIM ImmunoTech (NYSE:AIM) today announced it has entered into a Material Transfer and Research Agreement (MTA) with Shenzhen Smoore Technology Limited. According to a market

  4. AIM ImmunoTech Reports 2019 Year-end Financial Results

    OCALA, FL / ACCESSWIRE / March 31, 2020 / AIM ImmunoTech (NYSE:AIM) announces financial results for the fiscal year ended December 31, 2019, and provides a business update.2019 Financial HighlightsAs of December 31,

  5. AIM ImmunoTech Announces Further Efforts to Establish Clinical Trials Assessing Ampligen as a Potential Protective and Early-Onset Treatment for the Current COVID-19 Pandemic

    OCALA, FL / ACCESSWIRE / March 26, 2020 / AIM ImmunoTech (NYSE:AIM) today announced that it is actively seeking investigators and sites for clinical testing of Ampligen as a protective prophylaxis and an early-onset

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

CRL February 4, 2013.
Ampligen
CFS
Phase 1 data due around 2Q 2020.
Ampligen, Intron A, celecoxib and pembrolizumab
Triple-Negative Breast Cancer
Phase 2 interim data due around 2Q 2020.
Ampligen, Intron A, and celecoxib
Colorectal cancer
Phase 2 interim data due around 4Q 2020.
Ampligen, cisplatin and pembrolizumab
Ovarian cancer
Phase 2 trial to commence enrolment in 4Q 2019.
Ampligen, Intron A
Prostate Cancer
Phase 1 interim data to be presented 2020.
Ampligen plus Intron A
Ovarian cancer

Latest News

  1. AIM ImmunoTech and Shenzhen Smoore Technology Announce an Agreement to Research Utilizing an Innovative Smoore Inhalation Delivery Device and Ampligen (rintatolimod) as a Potential, Easy-To-Use Treatment Approach for the SARS-CoV-2 Pandemic

  2. AIM ImmunoTech Inc. General Corporate Statement (Form8) (0001493152-20-005912)

  3. AIM ImmunoTech and Shenzhen Smoore Technology Announce an Agreement to Research Utilizing an Innovative Smoore Inhalation Delivery Device and Ampligen (rintatolimod) as a Potential, Easy-To-Use Treatment Approach for the SARS-CoV-2 Pandemic

    OCALA, FL / ACCESSWIRE / April 6, 2020 / AIM ImmunoTech (NYSE:AIM) today announced it has entered into a Material Transfer and Research Agreement (MTA) with Shenzhen Smoore Technology Limited. According to a market

  4. AIM ImmunoTech Reports 2019 Year-end Financial Results

    OCALA, FL / ACCESSWIRE / March 31, 2020 / AIM ImmunoTech (NYSE:AIM) announces financial results for the fiscal year ended December 31, 2019, and provides a business update.2019 Financial HighlightsAs of December 31,

  5. AIM ImmunoTech Announces Further Efforts to Establish Clinical Trials Assessing Ampligen as a Potential Protective and Early-Onset Treatment for the Current COVID-19 Pandemic

    OCALA, FL / ACCESSWIRE / March 26, 2020 / AIM ImmunoTech (NYSE:AIM) today announced that it is actively seeking investigators and sites for clinical testing of Ampligen as a protective prophylaxis and an early-onset

  6. AIM ImmunoTech's Drug Ampligen to Be Tested by Japan's National Institute of Infectious Diseases as a Potential Treatment for the New SARS Coronavirus (SARS-CoV-2) Responsible for the New Human Infectious Disease COVID-19

    OCALA, FL / ACCESSWIRE / March 9, 2020 / AIM ImmunoTech (NYSE:AIM), an immuno-pharma company focused on the research and development of therapeutics to treat immune disorders, viral diseases and multiple types of

  7. AIM ImmunoTech Joins with ChinaGoAbroad for an Ampligen China Entry Against COVID-19, the New SARS-like Coronavirus Disease Epidemic

    OCALA, FL / ACCESSWIRE / February 27, 2020 / AIM ImmunoTech (NYSE:AIM, or the Company)), an immuno-pharma company focused on the research and development of therapeutics to treat immune disorders, viral diseases and

  8. AIM ImmunoTech公司向股东发布有关安普利近对抗武汉新型冠状病毒潜在作用的最新信息

    奥卡拉,佛罗里达州 – 2020年2月18日 – AIM

  9. AIM ImmunoTech Issues Stockholder Update on the Potential Role of Ampligen for Use Against the Wuhan Coronavirus Epidemic

    OCALA, FL / ACCESSWIRE / February 18, 2020 / AIM ImmunoTech (NYSE:AIM), an immuno-pharma company focused on the research and development of therapeutics to treat immune disorders, viral diseases and multiple types of

  10. AIM ImmunoTech提交了三項有關安普利近(R) 的臨時專利申請,以用於對抗類似SARS的武漢2019年新型冠狀病毒

    在針對SARS的動物實驗中,安普利近® 在臨床可達到的人體劑量水平下實現了100%的存活率安普利近是開發中的廣譜通用冠狀病毒疫苗的關鍵奧卡拉,佛羅里達州, 2020年2月11日 - (亞太商訊) - AIM

  11. AIM ImmunoTech's CEO to Appear Live Today on FOX Business Network's The Claman Countdown and Cheddar's Opening Bell to Discuss the Potential Role of Ampligen(R) for Use Against the Wuhan 2019 Novel Coronavirus

    OCALA, FL / ACCESSWIRE / February 12, 2020 / AIM ImmunoTech Inc. (NYSE:AIM), an immuno-pharma company focused on the research and development of therapeutics to treat immune disorders, viral diseases and multiple types

  12. AIM ImmunoTech Files Three Provisional Patent Applications Surrounding Ampligen(R) for Use Against the SARS-like Wuhan 2019 Novel Coronavirus

    Ampligen® obtained 100% survival rate at clinically achievable human dosage levels for SARS in animal experimentsAmpligen key to proposed broad-spectrum 'universal' coronavirus vaccineOCALA, FL / ACCESSWIRE

  13. AIM ImmunoTech Announces Completion of Third-Party Clinical Trial Using Ampligen in Combination with Other Therapies as Adjuvant Treatment of Peritoneal Surface Malignancies

    OCALA, FL / ACCESSWIRE / February 5, 2020 / AIM ImmunoTech Inc. (NYSE:AIM), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, today announced posting by

  14. AIM ImmunoTech to Present at the Investor Summit in Philadelphia

    OCALA, FL / ACCESSWIRE / December 11, 2019 / AIM ImmunoTech Inc. (NYSE:AIM), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, today announced that it

  15. AIM ImmunoTech Issues Stockholder Update and Details Its Expectations for 2020

    OCALA, FL / ACCESSWIRE / December 4, 2019 / AIM ImmunoTech (NYSE:AIM), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers and immune-deficiency diseases -

  16. CORRECTION: AIM ImmunoTech Provides Business Update for the Third Quarter of 2019

    This press release replaces the press release issued 11/15/2019 at 6:30 a.m., which included an incorrect date. The company had cash, cash equivalents and marketable securities of $1,825,000 as of December 31, 2018, not

  17. AIM ImmunoTech Provides Business Update for the Third Quarter of 2019

    OCALA, FL / ACCESSWIRE / November 15, 2019 / AIM ImmunoTech (NYSE:AIM), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers and immune-deficiency diseases -

  18. AIM ImmunoTech Provides Comprehensive Clinical Trials Update With Major Inflection Points Identified

    Well Capitalized to Complete Current Ampligen Clinical Trials Following $10M in Capital Raises Plus $15M Recently Awarded by DOD to Roswell Park and Moffitt for Ampligen-Related Breast Cancer TrialsOCALA, FL / ACCESSWIRE

  19. AIM ImmunoTech, Inc. Announces Pricing of $8 Million Public Offering

    OCALA, FL / ACCESSWIRE / September 25, 2019 / AIM ImmunoTech, Inc. (NYSE:AIM) (the "Company"), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of

  20. AIM ImmunoTech Inc. Announces a Second DoD Award, This One of $8.3 Million, to Fund Phase 2 Clinical Trial to Study Ampligen as Part of a New Treatment for Brain-Metastatic Breast Cancer at the Moffitt Cancer Center

    New Ampligen-Related Strategy for Treating Advanced Breast Cancer Helps Earn 'Breakthrough Award'OCALA, FL / ACCESSWIRE / September 24, 2019 / AIM ImmunoTech (NYSE:AIM), an immuno-pharma company focused on the

  21. AIM ImmunoTech's Ampligen Receives Clearance from FDA for Exportation to Argentina for the Treatment of Severe Chronic Fatigue Syndrome

    Important Milestone to Commercial Launch in Argentina AchievedOCALA, FL / ACCESSWIRE / September 24, 2019 / AIM ImmunoTech (NYSE:AIM), an immuno-pharma company focused on the research and development of therapeutics to

  22. AIM ImmunoTech Inc. Announces the U.S. Department of Defense's Award of $6.42M to Roswell Park Comprehensive Cancer Center to Study Ampligen as Part of a New Treatment of Brain-Metastatic Breast Cancer

    New Ampligen-Related Strategy for Treating Advanced Breast Cancer Earns 'Breakthrough Award'OCALA, FL / ACCESSWIRE / September 19, 2019 / AIM ImmunoTech Inc. (NYSE:AIM), an immuno-pharma company focused

  23. AIM ImmunoTech Names Ellen Lintal as New Chief Financial Officer

    OCALA, FL / ACCESSWIRE / September 16, 2019 / AIM ImmunoTech Inc. (NYSE:AIM), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers and immune-deficiency

  24. AIM ImmunoTech Inc. to Present at the Fall Investor Summit on September 16th-17th in New York City

    OCALA, FL / ACCESSWIRE / September 13, 2019 / AIM ImmunoTech Inc. (NYSE:AIM), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers and immune-deficiency

  25. AIM ImmunoTech Announces Progress Toward Opening of Breast Cancer Study at Roswell Park Comprehensive Cancer Center

    OCALA, FL / ACCESSWIRE / September 10, 2019 / AIM ImmunoTech Inc., (NYSE:AIM), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers and immune-deficiency